{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T20:31:18Z","timestamp":1782937878653,"version":"3.54.5"},"reference-count":49,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"unspecified","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"CRIS Investigator grant","award":["PR_TCL_2020-03"],"award-info":[{"award-number":["PR_TCL_2020-03"]}]},{"name":"Ministerio de Ciencia e Innovacion and the Agencia Estatal de Investigacion","award":["RTC2019-006860-1"],"award-info":[{"award-number":["RTC2019-006860-1"]}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"crossref","award":["PI20\/00434"],"award-info":[{"award-number":["PI20\/00434"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Fundacion cientifica asociaci\u00f3n espa\u00f1ola contra el cancer","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"crossref","award":["C18915\/A29362"],"award-info":[{"award-number":["C18915\/A29362"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2022,9,26]]},"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Radioimmunotherapy combines irradiation of tumor lesions with immunotherapy to achieve local and abscopal control of cancer. Most immunotherapy agents are given systemically, but strategies for delivering immunotherapy locally are under clinical scrutiny to maximize efficacy and avoid toxicity. Local immunotherapy, by injecting various pathogen-associated molecular patterns, has shown efficacy both preclinically and clinically. BO-112 is a viral mimetic based on nanoplexed double-stranded RNA (poly I:C) which exerts immune-mediated antitumor effects in mice and humans on intratumoral delivery. BO-112 and focal irradiation were used to make the proof-of-concept for local immunotherapy plus radiation therapy combinations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Murine transplantable tumor cell lines (TS\/A, MC38 and B16-OVA) were used to show increased immunogenic features under irradiation, as well as in bilateral tumor models in which only one of the lesions was irradiated or\/and injected with BO-112. Flow cytometry and multiplex tissue immunofluorescence were used to determine the effects on antitumor immunity. Depletions of immune cell populations and knockout mice for the IFNAR and BATF-3 genes were used to delineate the immune system requirements for efficacy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In cultures of TS\/A breast cancer cells, the combination of irradiation and BO-112 showed more prominent features of immunogenic tumor cell death in terms of calreticulin exposure. Injection of BO-112 into the tumor lesion receiving radiation achieved excellent control of the treated tumor and modest delays in contralateral tumor progression. Local effects were associated with more prominent infiltrates of antitumor cytotoxic tumor lymphocytes (CTLs). Importantly, local irradiation plus BO-112 in one of the tumor lesions that enhanced the therapeutic effects of radiotherapy on distant irradiated lesions that were not injected with BO-112. Hence, this beneficial effect of local irradiation plus BO-112 on a tumor lesion enhanced the therapeutic response to radiotherapy on distant non-injected lesions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This study demonstrates that local BO-112 immunotherapy and focal irradiation may act in synergy to achieve local tumor control. Irradiation plus BO-112 in one of the tumor lesions enhanced the therapeutic effects on distant irradiated lesions that were not injected with BO-112, suggesting strategies to treat oligometastatic patients with lesions susceptible to radiotherapy and with at least one tumor accessible for repeated BO-112 intratumoral injections.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2022-005011","type":"journal-article","created":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T10:52:01Z","timestamp":1673434321000},"page":"e005011","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":26,"title":["Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor control"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9765-2499","authenticated-orcid":false,"given":"Maria E","family":"Rodriguez-Ruiz","sequence":"first","affiliation":[{"name":"Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain"},{"name":"Navarra Institute for Health Research (IDISNA), Pamplona, Spain"},{"name":"Departments of Immunology-Immunotherapy and Oncology, Cl\u00ednica Universidad de Navarra, Pamplona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irantzu","family":"Serrano-Mendioroz","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eneko","family":"Garate-Soraluze","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paloma","family":"S\u00e1nchez-Mateos","sequence":"additional","affiliation":[{"name":"Departments of immunology and pathology, Hospital Gregorio Mara\u00f1on, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2789-1363","authenticated-orcid":false,"given":"Celia","family":"Barrio-Alonso","sequence":"additional","affiliation":[{"name":"Departments of immunology and pathology, Hospital Gregorio Mara\u00f1on, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Rodr\u00edguez L\u00f3pez","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain"},{"name":"Navarra Institute for Health Research (IDISNA), Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Diaz Pascual","sequence":"additional","affiliation":[{"name":"Departments of medical physic, Cl\u00ednica Universidad de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leire","family":"Arbea Moreno","sequence":"additional","affiliation":[{"name":"Departments of Immunology-Immunotherapy and Oncology, Cl\u00ednica Universidad de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5969-9181","authenticated-orcid":false,"given":"Maite","family":"Alvarez","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel F","family":"Sanmamed","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain"},{"name":"Navarra Institute for Health Research (IDISNA), Pamplona, Spain"},{"name":"Departments of Immunology-Immunotherapy and Oncology, Cl\u00ednica Universidad de Navarra, Pamplona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis","family":"Perez-Gracia","sequence":"additional","affiliation":[{"name":"Navarra Institute for Health Research (IDISNA), Pamplona, Spain"},{"name":"Departments of Immunology-Immunotherapy and Oncology, Cl\u00ednica Universidad de Navarra, Pamplona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Escuin-Ordinas","sequence":"additional","affiliation":[{"name":"Highlight Therapeutics, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisol","family":"Quintero","sequence":"additional","affiliation":[{"name":"Highlight Therapeutics, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1360-348X","authenticated-orcid":false,"given":"Ignacio","family":"Melero","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain"},{"name":"Navarra Institute for Health Research (IDISNA), Pamplona, Spain"},{"name":"Departments of Immunology-Immunotherapy and Oncology, Cl\u00ednica Universidad de Navarra, Pamplona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,1,11]]},"reference":[{"key":"2025100311211080000_11.1.e005011.1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx683"},{"key":"2025100311211080000_11.1.e005011.2","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-021-00507-y","article-title":"Intratumoural administration and tumour tissue targeting of cancer immunotherapies","volume":"18","author":"Melero","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"2025100311211080000_11.1.e005011.3","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001701","article-title":"Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany","volume":"9","author":"Ressler","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100311211080000_11.1.e005011.4","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.85.15.5374"},{"key":"2025100311211080000_11.1.e005011.5","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0743"},{"key":"2025100311211080000_11.1.e005011.6","first-page":"145","article-title":"Bacterial CpG-DNA licenses TLR9","volume":"270","author":"Bauer","year":"2002","journal-title":"Curr Top Microbiol Immunol"},{"key":"2025100311211080000_11.1.e005011.7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1866"},{"key":"2025100311211080000_11.1.e005011.8","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb0391","article-title":"Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors","volume":"12","author":"M\u00e1rquez-Rodas","year":"2020","journal-title":"Sci Transl Med"},{"key":"2025100311211080000_11.1.e005011.9","first-page":"A1011","article-title":"Preliminary results of a phase 2 study of intratumoral administration of bo-112 with pembrolizumab in patients with advanced melanoma that have progressive disease on anti-pd-1-based therapy","volume":"9","author":"Rodr\u00edguez-Moreno","year":"2021","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"2025100311211080000_11.1.e005011.10","first-page":"S867","article-title":"1057P - ROS1 mutation can serve- as a potential efficacious predictor of immunotherapy in melanoma patients","volume":"32","year":"2021","journal-title":"Annals of Oncology"},{"key":"2025100311211080000_11.1.e005011.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.07.004"},{"key":"2025100311211080000_11.1.e005011.12","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb0152","article-title":"Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma","volume":"12","author":"Kalbasi","year":"2020","journal-title":"Sci Transl Med"},{"key":"2025100311211080000_11.1.e005011.13","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0568-2"},{"key":"2025100311211080000_11.1.e005011.14","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002953"},{"key":"2025100311211080000_11.1.e005011.15","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1001\/jamaoncol.2015.2756","article-title":"Role of local radiation therapy in cancer immunotherapy","volume":"1","author":"Demaria","year":"2015","journal-title":"JAMA Oncol"},{"key":"2025100311211080000_11.1.e005011.16","first-page":"1229","article-title":"Effect of host immune capability on radiocurability and subsequent transplantability of a murine fibrosarcoma","volume":"63","author":"Stone","year":"1979","journal-title":"J Natl Cancer Inst"},{"key":"2025100311211080000_11.1.e005011.17","doi-asserted-by":"publisher","DOI":"10.4161\/21624011.2014.954929"},{"key":"2025100311211080000_11.1.e005011.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.semradonc.2014.07.005"},{"key":"2025100311211080000_11.1.e005011.19","doi-asserted-by":"publisher","DOI":"10.1038\/sj.emboj.7601127"},{"key":"2025100311211080000_11.1.e005011.20","doi-asserted-by":"publisher","DOI":"10.1172\/JCI67313"},{"key":"2025100311211080000_11.1.e005011.21","doi-asserted-by":"publisher","DOI":"10.1016\/bs.ai.2015.03.002"},{"key":"2025100311211080000_11.1.e005011.22","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-0549"},{"key":"2025100311211080000_11.1.e005011.23","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.107"},{"key":"2025100311211080000_11.1.e005011.24","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/1878-0261.12658","article-title":"Radiotherapy-immunotherapy combinations - perspectives and challenges","volume":"14","author":"Mondini","year":"2020","journal-title":"Mol Oncol"},{"key":"2025100311211080000_11.1.e005011.25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.2229"},{"key":"2025100311211080000_11.1.e005011.26","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0232-2"},{"key":"2025100311211080000_11.1.e005011.27","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1158\/1078-0432.728.11.2","article-title":"Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer","volume":"11","author":"Demaria","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2025100311211080000_11.1.e005011.28","doi-asserted-by":"publisher","DOI":"10.1038\/nature14292"},{"key":"2025100311211080000_11.1.e005011.29","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyaa268"},{"key":"2025100311211080000_11.1.e005011.30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-05-155457"},{"key":"2025100311211080000_11.1.e005011.31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-355222"},{"key":"2025100311211080000_11.1.e005011.32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.9793"},{"key":"2025100311211080000_11.1.e005011.33","doi-asserted-by":"crossref","DOI":"10.4161\/onci.25997","article-title":"The TLR7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer","volume":"2","author":"Demaria","year":"2013","journal-title":"Oncoimmunology"},{"key":"2025100311211080000_11.1.e005011.34","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0984"},{"key":"2025100311211080000_11.1.e005011.35","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0410-x"},{"key":"2025100311211080000_11.1.e005011.36","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy089"},{"key":"2025100311211080000_11.1.e005011.37","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2006.339"},{"key":"2025100311211080000_11.1.e005011.38","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1655964","article-title":"Apoptotic caspases inhibit abscopal responses to radiation and identify a new prognostic biomarker for breast cancer patients","volume":"8","author":"Rodriguez-Ruiz","year":"2019","journal-title":"Oncoimmunology"},{"key":"2025100311211080000_11.1.e005011.39","doi-asserted-by":"publisher","DOI":"10.1038\/emboj.2009.1"},{"key":"2025100311211080000_11.1.e005011.40","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/s41573-021-00155-y","article-title":"Beyond immune checkpoint blockade: emerging immunological strategies","volume":"20","author":"Kubli","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"2025100311211080000_11.1.e005011.41","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0003"},{"key":"2025100311211080000_11.1.e005011.42","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0317-y"},{"key":"2025100311211080000_11.1.e005011.43","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijrobp.2020.04.034","article-title":"Future of radiation and immunotherapy","volume":"108","author":"Formenti","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025100311211080000_11.1.e005011.44","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0265"},{"key":"2025100311211080000_11.1.e005011.45","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41590-019-0561-4","article-title":"Immunological impact of cell death signaling driven by radiation on the tumor microenvironment","volume":"21","author":"Rodriguez-Ruiz","year":"2020","journal-title":"Nat Immunol"},{"key":"2025100311211080000_11.1.e005011.46","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2015.00588","article-title":"Molecular and translational classifications of DAMPs in immunogenic cell death","volume":"6","author":"Garg","year":"2015","journal-title":"Front Immunol"},{"key":"2025100311211080000_11.1.e005011.47","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0510"},{"key":"2025100311211080000_11.1.e005011.48","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s43018-022-00401-1","article-title":"Charting roadmaps towards novel and safe synergistic immunotherapy combinations","volume":"3","author":"Sanmamed","year":"2022","journal-title":"Nat Cancer"},{"key":"2025100311211080000_11.1.e005011.49","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-3337"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2022-005011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T18:21:19Z","timestamp":1759515679000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2022-005011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1,11]]},"published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1136\/jitc-2022-005011"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2022-005011","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]}}}